ICON plc | Clinical Research Organisation (CRO) for Drug Development

Flow Cytometry for Driving Trials Forward

Engage assay experts with deep experience and expertise.

Charting the Managed Access Program Landscape

Plan for regulatory and operational challenges in managed access programs.

The Impact of AI on Outcomes Based Contracting

Understanding formulary decision maker & manufacturer challenges

Key Considerations in Chronic Pain Clinical Trials

Determine the right design, assessments and endpoints in your pain study

Featured Services

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

ICON Insights

03 December 2019

Healthcare Resource Use and Costs in AML Patients Undergoing Stem Cell Transplantation

ISPOR EU 2019 WINNER - Best General Poster Research Presentations: Health Care Use and Costs in Acute Myeloid Leukaemia (AML) Patients Undergoing Stem Cell Transplantation.

27 November 2019

Innovation in Oncology Drug Development

Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth.

22 November 2019

Top Five Digital Technologies Set to Transform Pharma R&D

The current wave of emerging digital technologies offers an opportunity to significantly disrupt pharma business operating models in a variety of ways.

19 November 2019

The Impact of Digital Technology on Patient Engagement in Clinical Trials

The use of digital technology in clinical trials is creating more convenient, engaging and innovative treatments for patients

15 November 2019

Payers Report that ICER Analyses Increasingly Guide US Price Negotiations

According to a survey conducted by ICON in July 2019, prescription drug cost effectiveness analyses by the Institute for Clinical and Economic Review (ICER) are playing an increasingly important role in price negotiations.

14 November 2019

Four Challenges to Successful Rare Disease Drug Development

Overcoming these challenges can greatly improve chances for a successful rare or orphan drug trial.

01 November 2019

Harnessing Big Data: The raw material of digital transformation

The integration and mastery of digital technologies is becoming essential to improve the efficiency of clinical trial operations.

31 October 2019

Challenges and Advances in NASH Clinical Trials

NASH is massively under-diagnosed, partly because it is a silent disease and partly because definitive diagnosis is by histopathology of a liver biopsy with associated risks.

29 October 2019

MDR / IVDR Regulatory Roundup

Less than one year remains before the European Union’s new Medical Device Regulation (MDR) goes into effect on May 26, 2020, and only about a fourth of medical device companies plan to be fully complaint,

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Developing medical communications specifically for nurses

How digital technologies will transform R&D productivity

Increasing complexity and declining ROI in drug development

Payer reliance on ICER assessments and perceptions on value-based pricing